We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
FDA已注册首个针对BPDCN的靶向治疗药物——pivekimab sunirin。缓解率69.7%，但存在风险。详细分析该药物及其后果。
